Abstract
A second oral antiviral for the early treatment of COVID-19 has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Paxlovid — a combination of two active ingredients, PF-07321332 and ritonavir — was approved after final trial results suggested a five-day treatment course reduced the risk of COVID-19-related hospitalisation and death within 28 days […]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
